Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss was found in 37.4% of surveyed rural high-school students in Eskisehir, Turkey, affecting their quality of life, especially in general health and mental well-being.

The document concludes that hair loss is complex, affects many people, has limited treatments, and requires more research on its causes and psychological impact.

Dupilumab can improve both atopic dermatitis and alopecia universalis.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Altered hypothalamic activity may contribute to stress in alopecia areata patients.

Telemedicine is effective for managing alopecia areata follow-ups.

Children with atopic diseases have a higher risk of developing alopecia areata.

Adults with alopecia areata often have empty follicular openings, while children show more honeycomb pigment patterns.

A mutation in the IL2RA gene increases the risk of alopecia areata.

AlopeciaDet accurately detects Alopecia Areata early using advanced image analysis.

Activated and non-activated PRP are equally safe and effective for treating alopecia areata.

Further research is needed to understand how the microbiome affects hair loss in Alopecia Areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.

Baricitinib is effective and safe for treating severe alopecia areata.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.

Hair loss in alopecia areata can negatively affect sexual quality of life.

Baricitinib is effective and safe for treating alopecia areata in Korea.

The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.

African American adults and non-White children experience more hair loss episodes than White patients with alopecia areata.

Alopecia areata patients have eye issues and need regular eye exams.

Microneedles combined with conventional therapies show promise in treating alopecia areata.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.